Orexo Ab · OMXSTO:ORX
Orexo Ab — Sthlm Corporate Finance CMD 2026
14 slides from Orexo Ab's conference presentation, Mar 17, 2026
Slide 1: Orexo cover
orexo a ooted _ . é ‘. Aes science, a pr oven in Ss = market’ >.” a
Slide 2: Legal disclaimer
2 Legal disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Or
Slide 3: This is Orexo
3 This is Orexo Comments Q2 Net Revenue LTM 1 Orexo is a pharmaceutical company dedicated to developing innovative medicines that save lives and address severe diseases. Our heritage - next-generation technology Development pipeline Founded in Uppsala, Sweden, with AmorphOX® is a powder-based drug d
Slide 4: Development pipeline and approved products
4 Development pipeline and approved products1 Technology Partnership Preclinical Clinical Registration Approved Development program Exploratory/ OX472 GLP-1 agonist, semaglutide – Large molecules Vaccine, influenza – Own projects/ OX640, epinephrine, incl. anaphylaxis – Small molecules OX390, NCE, o
Slide 5: AmorphOX
AmorphOxX AmorphOX? is a powder-based formulation technology that enables new and more effective solutions for the administration, manufacturing, and distribution of pharmaceuticals. VA Versatile applications V Superior bioavailability VA Stabilizes peptides and biologics VA Needle-free delivery
Slide 6: AmorphOX is a unique drug delivery technology
6 AmorphOX® is a unique drug delivery technology The challenge AmorphOX unique strengths Amorphous materials, commonly used in drug development, are rapidly absorbed but tend to be unstable limiting routes of administration, distribution and storage 1 AmorphOX unique properties ensure physical and c
Slide 7: The scalable AmorphOX platform takes Orexo beyond the OUD treatment area
7 The scalable AmorphOX® platform takes Orexo beyond the OUD treatment area Small Molecular weight (Mw) Large Small molecules Peptides Biologics Apomorphine Olanzapine Eletriptan Cetrorelix Semaglutide Enzyme Virus like Attenuated particle Virus Retained titer levels, Retained structure after Retain
Slide 8: Early stage projects: AmorphOX in large molecules
8 Early stage projects: AmorphOX® in large molecules In-vivo proof-of-concept study of With Abera Bioscience an in-vivo proof-of-concept study nasal semaglutide powders was conducted for a nasal powder vaccine IgG Serum AmorphOX formulations 1,6 1,4 Oral tablet Antibody response 1,2 1 0,8 0,6 0,4 0,
Slide 9: OX640 (clinical phase) – emergency treatment of anaphylaxis
9 OX640 (clinical phase) – emergency treatment of anaphylaxis In 2024 the first nasal product was approved in the US and EU which can pave the way for transformative shift 1 (intramuscular auto-injectors todays first line treatment) 2 Differentiating properties • Superior absorption and exposure • N
Slide 10: Orexo US awarded SEK 75 m by BARDA for OX390 development partnership
10 Orexo US awarded SEK 75 m by BARDA for OX390 development partnership1 Valued up to SEK 480 m and structured in six stages • OX390, today in preclinical stage, is specifically designed for adulterated overdoses where current treatments like naloxone or nalmefene are less effective • Addresses a hi
Slide 11: Izipry (registration phase) batches ready for stability and reliability studies
11 Izipry (registration phase) batches ready for stability and reliability studies Manufacturing of required batches at commercial scale initiated completed - a scalable in Q4 2025 drug delivery platform • Process initiated to complete the FDA required testing with expected resubmission in 2026 • St
Slide 12: Future value drivers
12 Future Future valuevalue drivers drivers
Slide 13: Approach for value growth
13 Approach for value growth Drive global leadership in amorphous powder ➢ Accelerate R&D and strengthen internal expertise to reinforce Orexo’s leadership in drug delivery based on amorphous powder formulations. for drug delivery. ➢ Strengthen the position within biomolecules advancing research int
Slide 14: Thanks
Orexo R&D Day Thanks www.orexo.com ➢ March 24, 2026 ➢ 9.30 am – 12 pm (followed by lunch) www.orexo.com ➢ IVA, Grev Turegatan 16 ➢ Registration on the website